Report: Steelers not expected to trade for Dolphins Pro Bowler
Report: Steelers not expected to trade for Dolphins Pro Bowler
Oh, what a difference a few days make for the Pittsburgh Steelers trade buzz.
Previously, insider Adam Schefter set off a trade speculation frenzy in the Steel City — reporting that the Steelers and Dolphins had engaged in trade talks regarding Miami's Pro Bowl TE Jonnu Smith. Five days later, however, Schefter has taken a different tone on the matter.
Packaged with Schefter's report on veteran WR Gabriel Davis visiting Pittsburgh, the long-time insider revealed that the Steelers were not expected to trade for Smith. Here's what he had to say on the situation:
"Pittsburgh has been seeking additional receiving help and has inquired about, but is not expected to trade for, Miami TE Jonnu Smith."
Insider Ian Rapoport had previously believed little would come of these trade talks — and one can't help but wonder if acquiring Smith would have made any difference for the already TE-sound Steelers offense.
For up-to-date Steelers coverage, follow us on X @TheSteelersWire and give our Facebook page a like.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Kansas City Chiefs OC Matt Nagy discusses Patrick Mahomes' evolution: ‘We can get better'
Kansas City Chiefs OC Matt Nagy discusses Patrick Mahomes' evolution: 'We can get better' The Kansas City Chiefs are focused on bigger plays on offense this season. Offensive coordinator Matt Nagy spoke with reporters on Wednesday, reflecting on Patrick Mahomes' evolution since his rookie season. 'There's been a lot. Obviously, the first year that we had him (Patrick Mahomes), it was just getting out of the huddle. You've heard about the calling the plays – all that stuff's easy now.' said Nagy, 'The defenses that we see – I think right now, more than anything, it's us being able to work routes with these wide receivers, these tight ends, these new running backs but for Pat, we always want to pick something that we can get better at and let him really lock in on, whether it's schematically or something that we did last year.' Last season was Mahomes' first as a starter without 4,000 passing yards or a Pro Bowl selection. Nagy believes he will bounce back with more efficiency in 2025. 'I think for us, everyone has numbers and everything of downfield throws and accuracy, inaccuracy, they do it, they don't do it – that's numbers, but the video shows what's going on.' said Nagy, 'We spend an ordinate amount of time breaking that down this offseason and watching it together. For what it's worth, at the end of the Eagles game – I know the score wasn't what we wanted, but there was a pretty good throw at the end of the year there to Xavier (Worthy), and I think that we're excited to get back to some of that.' Mahomes finished 2024 with 3,928 passing yards, 26 passing touchdowns, and 11 interceptions.
Miami Herald
an hour ago
- Miami Herald
Miami Hurricanes baseball team hoping to pull another upset in Louisville Super Regional
Another week, another long-odds road challenge for the Miami Hurricanes baseball team. Miami (34-25) will play at Louisville (38-21) on Friday, starting a best-of-three super regional, with the winner advancing to the College World Series next week in Omaha. Here are two reasons why Miami is an underdog: 1: Louisville is 27-7 at home. 2: Miami is 7-14 on the road. Then again, Miami beat the odds this past weekend, winning the four-team Hattiesburg Regional as the three seed. Miami edged host and top-seeded Southern Miss 5-4 on Monday night as the Hurricanes held on despite a two-run Golden Eagles homer in the bottom of the ninth. Miami has struggled at times this season, getting swept in three games by Wake Forest and Virginia. Miami has also dropped series to Florida; Connecticut; Florida State; North Carolina; and Notre Dame. The Hurricanes also lost their last two games before the Hattiesburg Regional to Notre Dame and Cal by identical 12-2 scores. Miami's improvement in Hattiesburg was due in part to the return to form of left fielder Derek Williams, who had missed five weeks following hand surgery. Williams' homer on Monday gave Miami a lead it never relinquished. 'I told you guys, Derek is a big piece in our lineup -- not just hitting but on the bases,' Miami coach J.D. Arteaga said. 'His homer got us going.' Williams is batting .331 with nine homers, a 1.028 OPS and 10 steals in 14 attempts (40 games). His presence in the fifth slot lengthens a batting order that is top heavy. Three-hole hitter Daniel Cuvet is Miami's star, leading the team in batting average (.379); OPS (1.170); doubles (19); homers (17); and RBIs (81). Overall, Arteaga feels pretty good about his top-six hitters in the batting order: leadoff man Jake Ogden, who is batting .345 and leads the team with 62 runs and a 13-for-13 rate on stolen bases; two-hole hitter Max Galvin (.301, .832 OPS); Cuvet third; cleanup batter Dorian Gonzalez (.805 OPS, second on the team with 11 homers); Williams fifth; and Tanner Smith sixth (.807 OPS). However, the bottom-three hitters in the lineup need to step up from Miami's perspective: first baseman Renzo Gonzalez (.615 OPS); right fielder Fabio Peralta (.625 OPS); and center fielder Michael Torres (.598 OPS). All three of them are good defenders, especially Torres. On the mound, the three key Hurricanes are starters AJ Ciscar (6-1, 3.78) and Griffin Hugus (6-7, 3.90 ERA); and closer Brian Walters (4.96 ERA, team-high 10 saves). In an ideal world for Miami, the Hurricanes win the series in two games. But if a third game is required, the pressure will be on freshman Tate DeRias (2-3, 5.77). DeRias took a loss to Southern Miss on Sunday, allowing nine runs in just two-thirds of an inning. Miami, which has won four national titles but none since 2001, is making its first super-regional appearance since 2016. Louisville, which has never won the College World Series, has earned 10 regional titles, including eight since 2013. Last season, the teams split four games. Louisville took two out of three games at home, but Miami got the Cardinals back by beating them at the ACC Tournament. The teams did not play this year during the regular season. The Cardinals won their 2025 regional – hosted by top overall seed Vanderbilt – in three straight games this past weekend. Louisville beat East Tennessee State, 8-3; knocked off Vanderbilt, 3-2; and defeated Wright State, 6-0. Louisville's three starting pitchers in the regional – Patrick Forbes; Tucker Biven: and Ethan Eberle – allowed just three earned runs in 17 innings (1.59 ERA). They also struck out 29 batters, including 13 by Forbes and 11 by Eberle. Offensively, the Cardinals are fast, led by Lucas Moore (48-for-49 on steals); Zion Rose (30-for-33); and Alex Alicea (30-for-36). The Cardinals also have home run power with Tague Davis (18 dingers); Eddie King Jr. (15); and Rose (12). Moore leads the team in hitting (.366) and runs (82). King, hitting .348, leads Louisville in extra-base hits (32). Jake Munroe, hitting .338, tops the squad with four triples. Alicea, hitting .316, leads the team in on-base percentage (.462). And Garrett Pike, batting .301, leads the team in doubles (17). Arteaga, though, is confident in his squad. 'This is a special group,' Arteaga said. 'This game rewards teams that do things the right way -- play hard, play with confidence and courage. 'All of that is this team to its core.'
Yahoo
an hour ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
